WORCESTER, Mass., June 9, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced presentations on the technologies and products under development at its wholly owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations were made at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 7 (www.asco.org) and at the Seventh World Congress on Vaccines, Immunization and Immunotherapy (WCVII) in Berlin, Germany on May 28.
The presentation at ASCO, entitled Effect of a Novel Ii-Key Hybrid HER2/neu Peptide AE37 Vaccine with GM-CSF as Compared to GM-CSF Alone on Levels of Regulatory T-cell Treg Populations was given by Guy Clifton. The study demonstrated that of 57 patients in the trial, 28 receiving GM-CSF adjuvant alone versus 27 patients receiving AE37 plus GM-CSF, there was a significant decrease in T regulatory cells only in patients treated with AE37. This is significant as T regulatory cells have been implicated in the suppression of anti-cancer immune responses. These results add to prior data demonstrating the immunological response to AE37 in patients as well as positive interim data from a randomized Phase II trial of AE37 in patients with breast cancer.
The podium presentation at WCVII in Berlin, Germany, entitled Immunotherapeutic and prophylactic vaccines using Ii-Key modified peptides for specific CD4+ T helper cell activation was given by Minzhen Xu, Vice President of Biology at Antigen Express. An overview of the technology, as well as specific development candidates for melanoma, influenza, and HPV, was presented. The WCVII is an international forum for investigators representing academia, industry, and biotech as well as government agencies interested in promoting the science and expertise in vaccinology and immunotherapy.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.